New hope for EGFR lung cancer: first human trial of ANS02 begins
Disease control
Not yet recruiting
This study tests a new drug called ANS02 in people with advanced non-small cell lung cancer that has a specific EGFR mutation. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 294 adults with good organ function and measur…
Phase: PHASE1, PHASE2 • Sponsor: Avistone Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC